Advertisement

Topics

Acerus Announces Approval of NATESTO in South Korea

12:42 EDT 14 Jun 2018 | Investing News Network

Acerus Pharmaceuticals (TSX:ASP) announced today that Hyundai Pharm Co., Ltd. (Hyundai), Acerus’ licensee, reported that South Korea’s Ministry of Food and Drug Safety (MFDS) has approved NATESTO® for the treatment of hypogonadism. As quoted in the press release: “Acerus is very pleased by the speed with which Hyundai has been able to prepare the dossier and … Continued

The post Acerus Announces Approval of NATESTO in South Korea appeared first on Investing News Network.

Original Article: Acerus Announces Approval of NATESTO in South Korea

NEXT ARTICLE

More From BioPortfolio on "Acerus Announces Approval of NATESTO in South Korea"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Food
Food is any substance consumed to provide nutritional support for the body. It is usually of plant or animal origin, and contains essential nutrients, such as carbohydrates, fats, proteins, vitamins, or minerals. The substance is ingested by an organism ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...